Guangji Pharmaceutical (000952.SZ) released its report for the first quarter of 2024, achieving an operating income of 1.8 during the reporting period...
According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 180 million yuan, an increase of 56.27% over the previous year. Net loss attributable to shareholders of listed companies was RMB 50,5082 million. The net loss of non-recurring profit and loss attributable to shareholders of the listed company was $57.554,500.
